New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
08:21 EDTPPHMPeregrine announces preclinical data presented on PS-targeting antibodies
Peregrine Pharmaceuticals announced that preclinical data presented at two Keystone Symposia support the immune-stimulatory mechanism of action and therapeutic potential of the company's phosphatidylserine, or PS,-targeting antibodies in both oncology and antiviral therapeutic areas. Peregrine's lead PS-targeting antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer, or NSCLC, as part of the SUNRISE pivotal Phase III clinical trial. In a poster titled, "Phosphatidylserine-Targeting Antibody Triggers -Chemokine Release from Monocytes by Cell-Cell Crosslinking and is a Potent Inhibitor of HIV-1 In Vitro", Cyril Empig, Ph.D., associate director of preclinical research in infectious disease at Peregrine, presented data from studies conducted by Duke University and Peregrine researchers that further characterizes the mechanism by which the PS-binding antibody PGN632 inhibits the HIV infection of cells. Results revealed that PGN632 stimulates immune cells to link together and secrete molecules that block viral receptors used by HIV to infect cells. Furthermore, the immune-stimulatory mechanism of PS-targeting antibodies was further validated as study results showed that the antiviral mechanism of action was dependent on using the full length antibody rather than an antibody fragment that simply blocks PS. In an oral presentation titled, "Phosphatidylserine-Targeting Antibodies Induce M1 Macrophage Polarization, Promote Myeloid Derived Suppressor Cell Differentiation and Boost Tumor-Specific Immunity" Xianming Huang, Ph.D., of The University of Texas Southwestern Medical Center in Dallas, presented data from studies demonstrating that PS-targeting antibodies override PS-mediated immune suppression in tumors and induce multiple downstream immune-stimulatory effects. Results showed a reduction of highly immunosuppressive myeloid derived suppressor cells, increases in inflammatory cytokines, tumor-fighting M1 macrophages, mature dendritic cells and tumor-specific cytotoxic T-cells. Additionally, combination therapy studies utilizing a PS-targeting antibody with an anti-PD-1 antibody yielded enhanced therapeutic results in a preclinical model of melanoma, including delays and reductions in tumor growth compared to either antibody administered alone.
News For PPHM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
09:47 EDTPPHMPeregrine says data trends continue to support bavituximab's potential in NSCLC
Subscribe for More Information
October 27, 2014
18:05 EDTPPHMNYC boy with Ebola-like symptoms tests negative for disease, WSJ says
Subscribe for More Information
11:24 EDTPPHMNovavax rises after announcing Ebola vaccine development program
Subscribe for More Information
07:27 EDTPPHMYoung NYC boy tested for Ebola, NY Post reports
Subscribe for More Information
October 26, 2014
14:40 EDTPPHMFDA issues Emergency Use Authorization for Ebola diagnostic tests
Subscribe for More Information
October 24, 2014
10:55 EDTPPHMDallas nurse now Ebola virus free, to be released, NBC reports
NBC and other media outlets cites NIH on Nina Pham's release. Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED). Reference Link
October 23, 2014
15:25 EDTPPHMNew York confirms health care worker being tested for Ebola
Subscribe for More Information
06:22 EDTPPHMEU to boost Ebola research with EUR 24.4M
The European Commission has today announced EUR 24.4M from the EU budget for urgently needed Ebola research. The funding will go to five projects, ranging from a large-scale clinical trial of a potential vaccine, to testing existing and novel compounds to treat Ebola. The money from Horizon 2020, the EU research and innovation program, will be provided via a fast-track procedure in order to start work as soon as possible. The Commission is also working with industry on the further development of vaccines, drugs and diagnostics for Ebola and other haemorrhagic diseases within the Innovative Medicines Initiative. The funding will be provided following proposals from teams across the EU and in numerous 3rd countries, which were evaluated by an independent group of experts. The Commission has also asked the European and Developing Countries Clinical Trials Partnership to include emerging epidemics of concern to Africa, including Ebola, in its work plan. This will allow to fund clinical trials on drugs, vaccines and diagnostics in upcoming calls. Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
October 22, 2014
06:41 EDTPPHMWHO fast-tracking testing of two Ebola vaccines, Guardian reports
Subscribe for More Information
October 17, 2014
14:50 EDTPPHMBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTPPHMSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use